Takeda's EXKIVITY (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC Seite 1

11.01.2023 - Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung ... Seite 1

Related Keywords

China ,Chinese ,Sean Shan ,Awny Farajallah ,Global Medical Affairs Oncology ,National Medical Products Administration ,Takeda Yakuhin Kogyo ,